FDA approved drugs for 2006

By pharmapsyche · Jan 31, 2006 · ·
  1. pharmapsyche
    The following drugs have recently been approved by the FDA for 2006, this
    includes newly approved drugs and new indications for drugs already approved
    by the FDA:

    Ranexa (ranolazine) Extended-Release Tablets
    Approved: January 27, 2006 Company: CV Therapeutics, Inc.
    Treatment for: Chronic Angina
    Ranexa is a novel antianginal and anti-ischemic agent indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs.

    Exubera Inhalation Powder
    Approved: January 27, 2006 Company: Pfizer Inc
    Treatment for: Type 1 and Type 2 Diabetes in Adults
    Exubera is a rapid-acting, dry powder human insulin that is inhaled through the mouth into the lungs prior to eating, using the handheld Exubera Inhaler. Exubera is indicated for the treatment of adult patients with diabetes mellitus, either as monotherapy, or in combination with oral agents or longer-acting insulins.

    Sutent (sunitinib malate) Capsules
    Approved: January 26, 2006 Company: Pfizer Inc.
    Treatment for: Gastrointestinal Stromal Tumors and Renal Carcinoma
    Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs). Sutent is indicated for the treatment of patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer.

    Taclonex (calcipotriene and betamethasone) Ointment
    Approved: January 10, 2006 Company: Warner Chilcott/LEO Pharma
    Treatment for: Psoriasis
    Taclonex is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of psoriasis vulgaris in adults.

    Vivaglobin (immune globulin subcutaneous) Injection
    Approved: January 9, 2006 Company: ZLB Behring
    Treatment for: Primary Immunodeficiencies
    Vivaglobin is a subcutaneous immunoglobulin (Ig) replacement therapy for treating patients with primary immunodeficiencies (PI).

    Boniva IV (ibandronate sodium) Injection
    Approved: January 6, 2006 Company: Roche/GlaxoSmithKline
    Treatment for: Postmenopausal Osteoporosis
    Boniva Injection is an intravenous formulation of the bisphosphonate drug ibandronate sodium, administered quarterly for the treatment of postmenopausal osteoporosis.

    Climara Pro (estradiol/levonorgestrel) Transdermal System
    First Approved: November 21, 2003 Company: Berlex, Inc.
    Treatment for: Menopausal Vasomotor Symptoms
    Climara Pro is a once-a-week, combined hormone therapy for the relief of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.
    New Indication Approved: January 4, 2006
    Treatment for: Prevention of Postmenopausal Osteoporosis
    Climara Pro is now also approved for the prevention of postmenopausal osteoporosis.

    Share This Article


  1. Alfa
    I don't see any psychoactives here.
To make a comment simply sign up and become a member!